Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SKL27969 |
| Synonyms | |
| Therapy Description |
SKL27969 inhibits PRMT5, potentially resulting in decreased cell proliferation and inhibition of tumor growth (Neuro Oncol 24, Supplement 7 (November 2022) vii233-vii234). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SKL27969 | SKL 27969|SKL-27969 | PRMT5 Inhibitor 21 | SKL27969 inhibits PRMT5, potentially resulting in decreased cell proliferation and inhibition of tumor growth (Neuro Oncol 24, Supplement 7 (November 2022) vii233-vii234). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05388435 | Phase Ib/II | SKL27969 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | Terminated | USA | 0 |